OSE Immunotherapeutics SA (EPA:OSE)

France flag France · Delayed Price · Currency is EUR
5.97
-0.04 (-0.58%)
May 12, 2025, 5:36 PM CET
-11.56%
Market Cap 133.04M
Revenue (ttm) 83.44M
Net Income (ttm) 37.45M
Shares Out 22.29M
EPS (ttm) 1.48
PE Ratio 4.03
Forward PE 6.60
Dividend n/a
Ex-Dividend Date n/a
Volume 100,139
Average Volume 124,174
Open 6.02
Previous Close 6.01
Day's Range 5.93 - 6.18
52-Week Range 4.42 - 11.58
Beta 0.58
RSI 50.81
Earnings Date Jun 26, 2025

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 55
Stock Exchange Euronext Paris
Ticker Symbol OSE
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.